Professionals deliberate the progression of Immuno-Oncology combinations while also engaging in conversations regarding the issue of immunotherapy resistance.
medicine might have in terms of toxicities. from that point test how effective it is in patients. that would be phase 2. carley: dr. malkas, to hear it destroys tumors, i don t know a lot about this but that sounds encouraging to me. we have done a lot of work in both cell cultures in-vitro throw models as well as in animal tumor models, and that s what gave us great encouragement and enthusiasm for moving the work forward. you know, it s based on the science, as dr. alvarnas indicated novel molecular target that is very cancer selective in that it kills the therapeutic kills cancer cells while leaving normal cells alone. we have great hopes in terms of it not only being a